1567P - A multi-institutional surveillance of clinicopathological features and molecular epidemiology of EGFR mutations in lung cancer patients living with...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cancer in Special Situations
Lung and other Thoracic Tumours
Pathology/Molecular Biology
Translational Research
Presenter Yusuke Okuma
Citation Annals of Oncology (2014) 25 (suppl_4): iv542-iv545. 10.1093/annonc/mdu357
Authors Y. Okuma1, J. Tanuma2, H. Otera3, Y. Kojima4, M. Yotsumoto5, T. Uehira3, Y. Takeda6, H. Nagai4, A. Ajisawa1, Y. Setoguchi5, S. Okada7
  • 1Department Of Thoracic Oncology And Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 2Aids Clinical Center, National Medical Center for Global Health and Medicine, Tokyo/JP
  • 3Department Of Infectious Diseases, National Hospital Organization Osaka National Hospital, Osaka/JP
  • 4Hematology And Oncology, National Hospital Organization, Nagoya Medical Center, Nagoya/JP
  • 5Departments Of Laboratory Medicine, Tokyo Medical University, Tokyo/JP
  • 6Respiratory Medicine, National Center for Global Health and Medicine, 162-8655 - Tokyo/JP
  • 7Center For Aids Research, Kumamoto University, Kumamoto/JP

Abstract

Aim

Lung cancer has become a crucial problem among patients living with human immunodeficiency virus (HIV), causing high mortality in Western countries. Japan has an increasing number of newly infected HIV patients. However, the clinical entities in the East-Asian population are unclear given the identification of ethnic differences in lung cancer in the general population.

Methods

Nationwide, retrospective surveillance of patients living with HIV diagnosed with lung cancer from 1986 to 2013 in Japan was performed. This study was supported by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan (Grant number: H25-AIDS-I-002).

Results

43 lung cancer patients living with HIV were diagnosed (median age, 60.0 years; males, 97.7%; 37.2% early stage, 34.9% advanced stage), 41 of whom were in the antiretroviral therapy era. The median CD4-positive T-cell count was 326 cells/µL. Adenocarcinoma was the most frequent histology (55.8%), followed by squamous cell carcinoma (27.9%). Of the 14 patients in whom epidermal growth factor receptor (EGFR) status was examined, 5 (35.7%) had EGFR mutations. Median overall survival was 25.1 months for all stages and 7.9 months for the advanced stage. On univariate and multivariate analyses, the only prognostic factor for overall survival was stage (p=0.02).

Conclusions

There appear to be ethnic differences in the prevalence of EGFR mutations even in the population living with HIV and the clinical characteristics or outcome may be provided in the regional differences.

Disclosure

All authors have declared no conflicts of interest.